Anti-obesity drugs: a critical review of current therapies and future opportunities
Introduction
It is clear to people living in the Western world that obesity is increasing, probably as a consequence of easily available, fat-rich food and an increasingly sedentary lifestyle. Interacting with the cultural changes is the influence of genetic predisposition, which is most easily demonstrated in populations that have evolved in situations where food supply was variable, for example, the North American Pima Indians. However, the genetic liability for the vast majority of the population does not reside in a single gene: obesity is a multigenic disorder. What is not apparently clear to people living in the Western world is the major health burden of obesity, not just in terms of the increased risk of Type 2 diabetes, cardiovascular morbidity, and cancer, but also in the economic costs to healthcare providers (McIntyre, 1998).
The obvious recourse to diet and exercise in the treatment of obesity is successful in just a small minority. When all else fails, many morbidly obese patients resort to surgical intervention, which, although effective, is not without risk in itself; risk exacerbated by gross overweight. There is a clear need for effective pharmaceutical intervention, but this appears to be an area in medicine with a very limited armamentarium, even today. The most effective drug treatment, a combination of fenfluramine with phentermine, could, in combination with diet, produce up to 30% reductions in body weight, but was withdrawn in 1997 when fenfluramine was found to cause valvular heart disease. The drug treatments on offer today are limited in their efficacy: in combination with diet, 10–15% reduction of body weight, of which at best 5% is attributable to the drug. Doubts have been raised on the long-term sustainability of this weight loss (Kolanowski, 1999). However, the health benefits of modest reductions in body weight have been recognised since the early 1990s Goldstein, 1992, Van Gaal et al., 1997.
In this article, we review existing drug therapies, but we also focus on areas of potential productivity in the future. Over the last 5 years, there has been an explosion in our knowledge of the mechanisms involved in regulating feeding behaviour and cellular mechanisms involved in energy expenditure. A rich harvest of potential new drug targets have arisen from this research, which may offer hope of safe and effective treatments for obesity. An indication of the potential impact of this research on new anti-obesity drugs is illustrated in Table 1, which lists drugs at Phase II of clinical trials or beyond. This review is broadly divided into drugs and drug targets influencing energy intake and factors affecting energy expenditure, although it must be recognised that many centrally acting “anorectic” drugs may also stimulate energy expenditure Arch, 1981, Picard et al., 1999.
Section snippets
Biogenic amines
Until recently, the only widely approved agents for the treatment of obesity were centrally acting appetite suppressants or anorectic agents. Even now, drug therapy options for obesity remain very limited, in spite of the epidemic scale of the disease. Public and practitioner perception of drug treatment of obesity has also been severely affected by the withdrawal of fenfluramine and dexfenfluramine in September 1997 as a result of mounting reports of heart valve defects. The centrally acting
Ephedrine/caffeine
Ephedrine (Fig. 10) is not new to medicine. It was first isolated over 100 years ago from the Asian plant ma huang, one of 40 species of the plant genus Ephedra, which itself has been used as a herbal remedy in Chinese medicine for over 2000 years. Today, ephedrine is widely available in over-the-counter remedies for nasal congestion and hay fever. Another well-established property of ephedrine is its anorectic activity and, hence, its use as an obesity treatment.
Following its introduction as
Future perspectives
The last 25 years have seen great increases in the incidence of obesity, but limited progress in the development of new anti-obesity drugs. The older agents have come under increasing pressure from regulatory agencies, and fenfluramine and dexfenfluramine have been withdrawn. To offset this bleak picture, orlistat and, in the United States, sibutramine recently have been approved, but sibutramine owes its discovery to its investigation in humans as an anti-depressant, its effect on body weight
References (479)
- et al.
Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behaviour and insulin secretion
Mol Brain Res
(1994) - et al.
Long-term maintenance of weight loss after a very-low-calorie diet, a randomized blinded trial of the efficacy and tolerability of sibutramine
Am J Med
(1999) The contribution of increased thermogenesis to the effect of anorectic drugs on body composition in mice
Am J Clin Nutr
(1981)- et al.
Thermogenic and anti-obesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats
Am J Clin Nutr
(1983) - et al.
Thermogenic and anorectic effects of ephedrine and congeners in mice and rats
Life Sci
(1982) - et al.
Thermogenic synergism between ephedrine and caffeine in healthy volunteers, a double-blind, placebo-controlled study
Metabolism
(1991) - et al.
Pharmacology of thermogenic drugs
Am J Clin Nutr
(1992) - et al.
Insulin treatment stimulates the rat MCH producing neurons
Neuropeptides
(1994) - et al.
Binding of enterostatin to the human neuroepithelioma cell line SK-N-MC
Peptides
(1998) - et al.
Distribution of β3-adrenoceptor mRNA in human tissues
Eur J Pharmacol
(1995)
Melanin-concentrating hormone and neuropeptide EI projections from the lateral hypothalamic area and zona incerta to the medial septal nucleus and spinal cord, a study using multiple neuronal tracers
Brain Res
The role of SOCS-3 in leptin signaling and leptin resistance
J Biol Chem
Identification of SOC-3 as a potential mediator of central leptin resistance
Mol Cell
Uncoupling protein-3 expression in skeletal muscle and free fatty acids in obesity
Lancet
Tissue-dependent upregulation of rat uncoupling protein-2 expression in response to fasting or cold
FEBS Lett
Uncoupling protein-3 expression in rodent skeletal muscle is modulated by food intake but not by changes in environmental temperature
J Biol Chem
Uncoupling protein-3 — a new member of the mitochondrial carrier family with tissue-specific expression
FEBS Lett
Metabolism of enterostatin in rat intestine, brain membranes, and serum, differential involvement of proline-specific peptidases
Peptides
The pharmacology of sibutramine hydrochloride (BTS 54 524). A new antidepressant which induces rapid noradrenergic down-regulation
Prog Neuropsychopharm Biol Psychiatry
Down-regulation of orexin gene expression by severe obesity in the rat: studies in Zucker fatty and Zucker diabetic fatty rat and effects of rosiglitazone
Mol Brain Res
Appetite and weight in children treated for ADHD
J Am Acad Child Adolesc Psychiatry
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation
Cell
Exocrine gland dysfunction in MC5-R-deficient mice, evidence for coordinated regulation of exocrine gland function by melanocortin peptides
Cell
Effects of the β2-adrenoceptor agonist, clenbuterol, on muscle atrophy due to food deprivation in the rat
Metabolism
Biochemical and histochemical characterization of ranatensin peptides
Brain Res
Histamine H3 receptor-mediated modulation of water consumption in the rat
Eur J Pharmacol
Effects of Citrus aurantium extract, caffeine, and St. John's Wort on body fat loss, lipid levels, and mood states in overweight healthy adults
Curr Ther Res Clin Exp
Integration of NPY, AgRP, and melanocortin signals in the hypothalamic paraventricular nucleus, evidence of a cellular basis for the adipostat
Neuron
Biological actions of galanin
Regul Pept
Galanin receptor antagonists M40 and C7 block galanin-induced feeding
Brain Res
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release buproprion and sertraline
Clin Ther
Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor
Biochem Biophys Res Commun
Endocannabinoids, endogenous cannabinoid receptor ligands with neuromodulatory action
Trends Neurosci
Galanin-containing neurons in the paraventricular nucleus: a neurochemical marker for fat ingestion and body weight gain
Proc Natl Acad Sci USA
Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats
Obes Res
Meta-analysis of the association of the Trp64Arg polymorphism in the beta(3) adrenergic receptor with body mass index
Int J Obes
Expression of the glucagon-like peptide-1 receptor gene in rat brain
J Neurochem
Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes
Experientia
β3-Adrenoceptor ligands and the pharmacology of β3-adrenoceptors
Prospects for β3-adrenoceptor agonists in the treatment of obesity and diabetes
Int J Obes
Treatment of obesity with thermogenic β-adrenoceptor agonists, studies on BRL 26830A in rodents
Int J Obes
Influences on body composition and mechanism of action of the β-adrenoceptor agonist BRL 26830A
β-Adrenoceptor-mediated control of thermogenesis, body composition and glucose homeostasis
Orexins, new neuropeptide receptor targets for anti-obesity drugs?
Int J Obes
Leptin resistance in obese humans: does it exist and what does it mean
Int J Obes
The CB1 cannabinoid receptor antagonist SR141716 reduces sucrose intake and fat diet preference in lean and obese rats
Int J Obes
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors
Psychopharmacology
Pharmacological and clinical studies of ephedrine and other thermogenic agonists
Obes Res
The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial
Int J Obes
Thermogenic, metabolic and cardiovascular effects of a sympathetomimetic agent ephedrine
Curr Ther Res Clin Exp
Cited by (101)
Effect of palmitoylated prolactin-releasing peptide on food intake and neural activation after different routes of peripheral administration in rats
2016, PeptidesCitation Excerpt :Many neuropeptides affect food intake when injected into the hypothalamus, a lateral brain ventricle, or the third ventricle [21]. Neuropeptide receptors are potential targets for anti-obesity treatment, because the neuropeptides play a physiological role in the regulation of feeding [13]. This is true for several neuropeptides, including prolactin-releasing peptide.
Appetite Regulation and Thermogenesis
2015, Endocrinology: Adult and PediatricAntiobesity effect of a jelly food containing the L-tryptophan derivative of Monascus pigment in mice
2014, Journal of Functional FoodsCitation Excerpt :Obesity is a serious problem around the world contributing to diabetes, hypertension, cardiovascular diseases, and cancers of the small intestine, uterus, and breast (Balsiger, Murr, Poggio, & Sarr, 2000). In many cases, treatment of obesity depends on drugs and foodstuffs (Baboota et al., 2013; Clapham, Arch, & Tadayyon, 2001; Jin et al., 2013; Pangestuti & Kim, 2011). Antiobesity drugs have various functions, including reduction of food intake, alteration of the metabolism, and an increase in thermogenesis (Bray, 2000).